To our knowledge, this is the first report of a F1174S mutation in EML4-ALK positive NSCLC, and our work highlights the complexity of oncogenic drivers and their resistance mechanisms in EML4-ALK positive lung cancer patients. This evidence concerns the gene ALK and lung carcinoma.